Fisher & Paykel Healthcare (ASX:FPH) Releases Revenue Forecast – The Market Herald
- Fisher & Paykel Healthcare (FPH) has provided revenue guidance for the fiscal year ending March 31, 2022
- The Auckland-based healthcare company expects operating revenue for the 2022 financial year to be between $1.675 billion and $1.70 billion.
- Despite supply chain constraints, sales of the company’s Homecare product group of OSA masks are currently tracking a higher growth rate than the first half.
- The company intends to release its financial results for the year ending March 31 on May 25.
- Fisher & Paykel Healthcare shares were flat at $25.76
Fisher & Paykel Healthcare (FPH) has provided revenue forecasts for the fiscal year ending March 31, 2022.
The Auckland-based healthcare company expects operating revenue for the 2022 financial year to be between $1.675 billion and $1.7 billion.
With uncertainty surrounding COVID-19, vaccinations and lockdowns when releasing its annual results in May last year, Fisher & Paykel did not provide guidance for FY22.
He said today that despite supply chain constraints, sales of the company’s Homecare product group of OSA masks are currently tracking a higher growth rate than the first half.
Freight rates remain high and for fiscal 2022 are expected to impact the company’s long-term gross margin target of 65% by approximately 250 basis points.
The company intends to release its financial results for the year ending March 31 on May 25.
“Our second half hospital consumables revenue is currently similar to what we reported in the first half of fiscal 2022. This is consistent with reports of increasing prevalence of the Omicron variant over the past two months and associated lower respiratory response requirements, as well as a relatively mild influenza season in the Northern Hemisphere,†said Managing Director and CEO Lewis Gradon.
“Regardless of how the effects of COVID-19 play out in the short term, we believe our company is well positioned to contribute to positive change in clinical practice and improved outcomes for respiratory patients overall. on the long term.
FPH specializes in the design, manufacture and marketing of products and systems for acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.
Shares in the company were unchanged at $25.76 at 9:56 a.m. AEDT.
